Alzheimer Disease Clinical Trial
Official title:
Prevalence and Detection of Voice and Swallowing Disorders in Adults With and Without Alzheimer's Disease
NCT number | NCT06328374 |
Other study ID # | 240420 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 2024 |
Est. completion date | December 2026 |
This research study is investigating whether people with Alzheimer's disease experience more changes to voice and swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe Alzheimer's Disease is high (85-93%) and voice is also often negatively impacted by Alzheimer's disease. The overall objective of this study is to evaluate the voice and swallowing function of adults with and without Alzheimer's disease. The investigators will also be involving the primary caregivers of individuals with Alzheimer's that are enrolled in the study to better understand the impact of voice and swallowing impairments on the primary caregivers of those with Alzheimer's Disease. Healthy adults and individuals with Alzheimer's disease will: - undergo tests of cough, voice, and swallow function - undergo tests of grip and tongue strength - complete questionnaires Caregivers of individuals with Alzheimer's disease will also complete questionnaires.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | December 2026 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 100 Years |
Eligibility | Healthy Adult Cohort Inclusion Criteria 1. healthy community dwelling adult (60-100 years old) 2. no prior history of neurological diseases 3. no prior history of respiratory diseases 4. no prior history of head and neck surgery/head and neck cancer/radiation to head and neck region 5. no prior history of swallowing difficulties 6. no prior history of gastroesophageal diseases/impairments 7. absence of vocal fold lesions or paresis/paralysis 8. no recent intubation (=3 weeks) 9. score =26 on the Montreal Cognitive Assessment (MOCA) or the telephone version of the MOCA (t-MOCA) Exclusion Criteria 1. individual <60 years old, >100 years old 2. history of neurological disease 3. history of respiratory disease 4. history of head and neck surgery/head and neck cancer/radiation to head and neck region 5. history of swallowing difficulties 6. history of gastroesophageal diseases/impairments 7. presence of vocal fold lesions or paresis/paralysis 8. recent intubation (<3 weeks) 9. score <26 on the Montreal Cognitive Assessment (MOCA) or the telephone version of the MOCA (t-MOCA) AD Cohort Inclusion Criteria 1. between 60-100 years old 2. diagnosis of AD by neurologist 3. consuming some form of oral intake 4. able to follow basic directions Exclusion Criteria 1. individual <60 years old, >100 years old 2. diagnosis of another type of dementia 3. not consuming any oral intake 4. unable to follow basic directions Caregivers of Individuals with AD Cohort Inclusion Criteria 1. primary caregiver of an individual with AD 2. willing to complete questionnaires/semi-structured interview Exclusion Criteria 1. not the primary caregiver of an individual with AD 2. unwilling to complete questionnaires/semi-structured interview |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Swallowing safety | The penetration aspiration scale is a validated 8-point ordinal rating scale that measures the depth of airway invasion and the patient's response during swallowing. Scores range from 1 to 8 with a score of 1 indicating a safe swallow (best score) and 8 indicating silent aspiration (worst score). | During baseline visit at time of enrollment. | |
Primary | Voluntary cough peak expiratory flow | A measure of cough strength | During baseline visit at time of enrollment. | |
Primary | Vocal fold bowing index | Vocal fold bowing will be completed as described by Bloch and Behrman. | During baseline visit at time of enrollment. | |
Secondary | Swallowing and Eating Related Fatigue Questionnaire (SERF) | Scores on the SERF range 0-48 with higher scores indicating greater impairment. | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. | |
Secondary | Swallowing Related Quality of Life Questionnaire (SWAL-QOL) | Scores on the SWAL-QOL range from 0-100 with lower scores indicating greater impairment. | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. | |
Secondary | Voice Handicap Index (VHI) | The VHI contains 30 questions, and scores range from 0-120, with higher scores indicating greater perceived voice handicap. | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. | |
Secondary | Aging Voice Index (AVI) | he AVI consists of 23 questions, with scores ranging from 0-92. Higher scores indicate a greater effect of dysphonia on quality of life. | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. | |
Secondary | Grip Strength | Grip strength be used to quantify clinical frailty using a digital hand dynamometer. | During baseline visit at time of enrollment. | |
Secondary | Tongue strength | Tongue strength will be assessed using the Iowa Oral Pressure Instrument (IOPI). | During baseline visit at time of enrollment. | |
Secondary | Clinical frailty scale | The clinical frailty scale (scores 1-9) will be used to classify frailty with higher scores indicating greater impairment. | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. | |
Secondary | Caregiver Analysis of Reported Experiences with Swallowing Disorders (CARES) Questionnaire | Scores on the CARES range from 0-26 with higher scores indicating greater caregiver burden. | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. | |
Secondary | Caregiver Self-Assessment Questionnaire | Scores range from 0-16 with higher scores indicating greater caregiver burden | During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |